{"nctId":"NCT00352053","briefTitle":"Safety and Efficacy of Tenofovir DF in HIV-1 Infected Adolescents Failing Their Current Antiretroviral Therapy","startDateStruct":{"date":"2006-06"},"conditions":["HIV Infections"],"count":87,"armGroups":[{"label":"OBR + Tenofovir DF","type":"EXPERIMENTAL","interventionNames":["Drug: Tenofovir DF"]},{"label":"OBR + Tenofovir DF Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Tenofovir DF","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Major Inclusion Criteria:\n\n* Weight ≥ 35 kg\n* Documented laboratory diagnosis of HIV infection\n* Plasma HIV-1 RNA ≥ 1000 copies/mL\n* Prior antiretroviral treatment experience with at least 2 antiretroviral drug classes\n* Naive to tenofovir DF\n* Absence of K65R mutation on genotypic testing\n\nExclusion Criteria:\n\n* Patients requiring didanosine in background regimen\n* Prior history of significant renal disease\n* Prior history of significant bone disease","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time-weighted Average Change From Baseline Through Week 24 (DAVG24) in Plasma HIV-1 RNA","description":"DAVG24 was defined as the time-weighted average between the first postbaseline value through the last value up to Week 24 minus the baseline value. DAVG24 was calculated using the trapezoidal rule with all available postbaseline data minus the baseline value.\n\nData for participants who discontinued the randomized (double-blind) phase of the study early were included up until the point of study discontinuation (missing data not imputed).","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.580","spread":null},{"groupId":"OG001","value":"-1.549","spread":null}]}]}]},{"type":"SECONDARY","title":"Time-weighted Average Change From Baseline Through Week 48 (DAVG48) in Plasma HIV-1 RNA","description":"DAVG48 was defined as the time-weighted average between the first postbaseline value through the last value up to Week 48 minus the baseline value. DAVG48 was calculated using the trapezoidal rule with all available postbaseline data minus the baseline value.\n\nData for participants who discontinued the double-blind phase of the study early were included up until the point of discontinuation from the study (ie, missing data were not imputed).","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.423","spread":null},{"groupId":"OG001","value":"-1.352","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 24 in HIV-1 RNA","description":null,"paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.23","spread":null},{"groupId":"OG001","value":"-1.27","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"-0.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 48 in HIV-1 RNA","description":null,"paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.97","spread":null},{"groupId":"OG001","value":"-1.53","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 96 in HIV-1 RNA","description":null,"paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 144 in HIV-1 RNA","description":null,"paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":null},{"groupId":"OG001","value":"0.2","spread":null},{"groupId":"OG002","value":"0.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 192 in HIV-1 RNA","description":null,"paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"-0.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 240 in HIV-1 RNA","description":null,"paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":null},{"groupId":"OG001","value":"-0.4","spread":null},{"groupId":"OG002","value":"-1.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 288 in HIV-1 RNA","description":null,"paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":null},{"groupId":"OG001","value":"-0.8","spread":null},{"groupId":"OG002","value":"0.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 336 in HIV-1 RNA","description":"No analysis was performed because the last study participant discontinued after Week 294 and the study was closed.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Change From Baseline to Week 24 in Cluster Determinant 4 (CD4) Count","description":null,"paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"49","spread":null},{"groupId":"OG002","value":"-43","spread":null},{"groupId":"OG003","value":"-12","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 48 in CD4 Count","description":null,"paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"152","spread":null},{"groupId":"OG001","value":"148","spread":null},{"groupId":"OG002","value":"15","spread":null},{"groupId":"OG003","value":"-47","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 96 in CD4 Count","description":null,"paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"152","spread":null},{"groupId":"OG001","value":"-6","spread":null},{"groupId":"OG002","value":"-69","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 144 in CD4 Count","description":null,"paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"188","spread":null},{"groupId":"OG001","value":"-88","spread":null},{"groupId":"OG002","value":"33","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 192 in CD4 Count","description":null,"paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"166","spread":null},{"groupId":"OG001","value":"-70","spread":null},{"groupId":"OG002","value":"-23","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 240 in CD4 Count","description":null,"paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"221","spread":null},{"groupId":"OG001","value":"571","spread":null},{"groupId":"OG002","value":"258","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 288 in CD4 Count","description":null,"paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"310","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"309","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 336 in CD4 Count","description":"No analysis was performed because the last study participant discontinued after Week 294 and the study was closed.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Change From Baseline to Week 24 in CD4 Percentage","description":"CD4 percentage is the percentage of total lymphocytes that are CD4 cells.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":null},{"groupId":"OG001","value":"2.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"-1.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 48 in CD4 Percentage","description":"CD4 percentage is the percentage of total lymphocytes that are CD4 cells.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":null},{"groupId":"OG001","value":"5.0","spread":null},{"groupId":"OG002","value":"2.0","spread":null},{"groupId":"OG003","value":"-1.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 96 in CD4 Percentage","description":"CD4 percentage is the percentage of total lymphocytes that are CD4 cells.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":null},{"groupId":"OG001","value":"2.0","spread":null},{"groupId":"OG002","value":"9.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 144 in CD4 Percentage","description":"CD4 percentage is the percentage of total lymphocytes that are CD4 cells.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"5.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 192 in CD4 Percentage","description":"CD4 percentage is the percentage of total lymphocytes that are CD4 cells.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":null},{"groupId":"OG001","value":"1.9","spread":null},{"groupId":"OG002","value":"4.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 240 in CD4 Percentage","description":"CD4 percentage is the percentage of total lymphocytes that are CD4 cells.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":null},{"groupId":"OG001","value":"8.9","spread":null},{"groupId":"OG002","value":"18.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 288 in CD4 Percentage","description":"CD4 percentage is the percentage of total lymphocytes that are CD4 cells.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":null},{"groupId":"OG001","value":"4.0","spread":null},{"groupId":"OG002","value":"11.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 336 in CD4 Percentage","description":"No analysis was performed because the last study participant discontinued after Week 294 and the study was closed.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 24","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.8","spread":null},{"groupId":"OG001","value":"51.2","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"12.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 48","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.7","spread":null},{"groupId":"OG001","value":"53.7","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 96","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.7","spread":null},{"groupId":"OG001","value":"5.9","spread":null},{"groupId":"OG002","value":"33.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 144","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 192","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.4","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"50.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 240","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0log 10 Copies/mL From Baseline to Week 288","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 336","description":"No analysis was performed because the last study participant discontinued after Week 294 and the study was closed.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 24","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.9","spread":null},{"groupId":"OG001","value":"41.5","spread":null},{"groupId":"OG002","value":"83.3","spread":null},{"groupId":"OG003","value":"6.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 48","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.1","spread":null},{"groupId":"OG001","value":"43.9","spread":null},{"groupId":"OG002","value":"77.8","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 96","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.2","spread":null},{"groupId":"OG001","value":"70.6","spread":null},{"groupId":"OG002","value":"33.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 144","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.0","spread":null},{"groupId":"OG001","value":"72.7","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 192","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.1","spread":null},{"groupId":"OG001","value":"80.0","spread":null},{"groupId":"OG002","value":"50.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 240","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 288","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 336","description":"No analysis was performed because the last study participant discontinued after Week 294 and the study was closed.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.5","spread":null},{"groupId":"OG001","value":"34.1","spread":null},{"groupId":"OG002","value":"77.8","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.3","spread":null},{"groupId":"OG001","value":"36.6","spread":null},{"groupId":"OG002","value":"61.1","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.4","spread":null},{"groupId":"OG001","value":"58.8","spread":null},{"groupId":"OG002","value":"33.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 144","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.0","spread":null},{"groupId":"OG001","value":"45.5","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 192","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.9","spread":null},{"groupId":"OG001","value":"60.0","spread":null},{"groupId":"OG002","value":"50.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 240","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 288","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 336","description":"No analysis was performed because the last study participant discontinued after Week 294 and the study was closed.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Percentage of Participants With Virologic Failure Through Week 48","description":"Virologic failure was defined as either nonresponse or viral rebound.\n\n* Nonresponse (failure to achieve response). Response was defined as either\n\n  * A ≥ 0.5 log10 copies/mL decrease in HIV-1 RNA from baseline at 2 consecutive visits, or\n  * HIV-1 RNA \\< 400 copies/mL at 2 consecutive visits.\n* Viral rebound was defined as either\n\n  * Participants who achieved a ≥ 0.5 log10 copies/mL decrease from baseline in plasma HIV-1 RNA at 2 consecutive visits, who then subsequently achieved plasma HIV-1 RNA values ≥ 1.0 log10 copies/mL above their on-study nadir (lowest value) and/or plasma HIV-1 RNA values ≥ the baseline value at 2 consecutive visits, or\n  * Participants who achieved plasma HIV-1 RNA levels of \\< 400 copies/mL at 2 consecutive visits, and then subsequently had plasma HIV-1 RNA levels \\> 1000 copies/mL at 2 consecutive visits.\n\nThe virologic failure rate was estimated from Kaplan-Meier product limit method by including all HIV-1 RNA data collected during the double-blind phase.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":45},"commonTop":["Vomiting","Sinusitis","Cough","Nasopharyngitis","Diarrhoea"]}}}